ReviewFrontiers in medicine2025
Visual analysis of ovarian cancer immunotherapy: a bibliometric analysis from 2010 to 2025.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Bibliometric analysis of ovarian cancer immune evasion research from 2015 to 2024.Frontiers in oncology · 2025Pooled it
- Lipid metabolism in γδ T-cell activation: Implications for immunotherapy in ovarian cancer.Translational oncology · 2026Review
- Ovarian Tumor Biomarkers: Correlation Between Tumor Type and Marker Expression, and Their Role in Guiding Therapeutic Strategies.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on immunotherapy for ovarian cancer is rapidly advancing, and harnessing the immune system to fight tumors is at the forefront of cancer treatment. This article aims to discuss the prospect and development trend of immunotherapy for ovarian cancer from the perspective of bibliometrics. Articles about tumor burden and immunotherapy were collected from the Web of Science Core Collection (WoSCC) (retrieved on 1 May 2025). R package "Bibliometrics" analyzes key bibliometric characteristics and creates a three-filed map to show the relationships between institutions, countries, and keywords. VOSviewer is used for co-author analysis, co-occurrence analysis, and visualization. CiteSpace calculates citation burst citations and keywords. A total of 1,449 publications were retrieved from 15 years of scientific research. The China and United States (US) published the most articles. The most productive journals were Cancer Immunology Immunotherapy and Journal for Immunotherapy of Cancer. The top institution with the highest output was HARVARD UNIVERSITY. In recent years, the hot keywords of strong citation burst strength were "dendritic cells," "monoclonal antibody," and "adoptive immunotherapy." This bibliometric analysis mapped a basic knowledge structure. The tumor burden and immunotherapy field is entering a rapidly growing stage and keeping its value for future research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.